Literature DB >> 31410993

In vivo hydroxyapatite scaffold performance in infected bone defects.

Joseph J Pearson1,2, Nicholas Gerken2,3, Chunsik Bae4, Kyu-Bok Lee5, Arpan Satsangi1, Sean McBride6, Mark R Appleford1, David D Dean2,3, Jeffrey O Hollinger6, Joo L Ong1, Teja Guda1.   

Abstract

Critically sized bone defects are often compounded by infectious complications. The standard of care consists of bone autografts with systemic antibiotics. These injuries and treatments lead to donor site morbidity, antibiotic resistant strains of bacteria, and often end stage amputation. This study proposes an alternative to the autograft using a porous, hydroxyapatite (HA) scaffold evaluated with and without infection and antibiotics. Twenty-four New Zealand white rabbits received either our HA scaffold or a pulverized autograft (PBA) within a surgically created critical-sized defect in the femur. The two grafts were evaluated in either septic or aseptic defects and with or without antibiotic treatment. The HA scaffolds were characterized with micro computed tomography. Post-euthanasia, micro computed tomography, histology, and white blood cells component analysis were completed. The HA had significantly greater (p < .001) mineralization to total volume than the PBA groups with 27.56% and 14.88%, respectively, and the septic HA groups were significantly greater than the aseptic groups both with and without antibiotics (p = .016). The bone quality denoted by bone mineral density was also significantly greater (p < .001) in the HA groups (67.01 ± 0.38 mgHA/cm3 ) than the PBA groups (64.66 ± 0.85 mgHA/cm3 ). The HA scaffold is a viable alternative to the bone autograft in defects with and without infection as shown by the quality and quantity of bone.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  bone graft; calcium phosphate(s); hydroxyapatite; infection

Year:  2019        PMID: 31410993     DOI: 10.1002/jbm.b.34466

Source DB:  PubMed          Journal:  J Biomed Mater Res B Appl Biomater        ISSN: 1552-4973            Impact factor:   3.368


  6 in total

1.  Electrospun Membrane Surface Modification by Sonocoating with HA and ZnO:Ag Nanoparticles-Characterization and Evaluation of Osteoblasts and Bacterial Cell Behavior In Vitro.

Authors:  Julia Higuchi; Katarzyna Klimek; Jacek Wojnarowicz; Agnieszka Opalińska; Agnieszka Chodara; Urszula Szałaj; Sylwia Dąbrowska; Damian Fudala; Grazyna Ginalska
Journal:  Cells       Date:  2022-05-08       Impact factor: 7.666

2.  Application of vancomycin-impregnated calcium sulfate hemihydrate/nanohydroxyapatite/carboxymethyl chitosan injectable hydrogels combined with BMSC sheets for the treatment of infected bone defects in a rabbit model.

Authors:  Yanjun Wang; Zihou Zhao; Shiyu Liu; Wen Luo; Guoliang Wang; Zhenfeng Zhu; Qiong Ma; Yunyan Liu; Linhu Wang; Shuaikun Lu; Yong Zhang; Jixian Qian; Yunfei Zhang
Journal:  BMC Musculoskelet Disord       Date:  2022-06-09       Impact factor: 2.562

3.  Development of bioinks for 3D printing microporous, sintered calcium phosphate scaffolds.

Authors:  Sergio A Montelongo; Gennifer Chiou; Joo L Ong; Rena Bizios; Teja Guda
Journal:  J Mater Sci Mater Med       Date:  2021-08-14       Impact factor: 3.896

4.  Platelet-Derived Growth Factor-Functionalized Scaffolds for the Recruitment of Synovial Mesenchymal Stem Cells for Osteochondral Repair.

Authors:  Yuan Luo; Xiaodong Cao; Junfeng Chen; Jianwei Gu; Hao Yu; Junying Sun; Jun Zou
Journal:  Stem Cells Int       Date:  2022-01-27       Impact factor: 5.443

5.  Plate-associated localized osteitis in mini-pig by biofilm-forming Methicillin-resistant Staphylococcus aureus (MRSA): establishment of a novel experimental model.

Authors:  Carina Jaekel; Ceylan D Windolf; Martin Sager; Lena M Wollschläger; Martin Hoffmanns; Jan P Grassmann
Journal:  Eur J Trauma Emerg Surg       Date:  2022-02-24       Impact factor: 2.374

Review 6.  Bone Healing Materials in the Treatment of Recalcitrant Nonunions and Bone Defects.

Authors:  Emérito Carlos Rodríguez-Merchán
Journal:  Int J Mol Sci       Date:  2022-03-20       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.